This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Samuel Livingston, MD; Lydia L. Pauli, MD; Irving Pruce; Irving I. Kramer, MD
The Samuel Livingston Epilepsy Diagnostic and Treatment Center Baltimore

JAMA. 1979;241(18):1892.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

We are writing in regard to the article "Valproic Acid (Depakene): A New Anticonvulsant Agent" (240:2190, 1978), in which Lewis presented a succinct review of the literature relative to the efficacy and toxicity of this drug. His conclusion that valproic acid "is most effective in absence seizures (simple and complex)" and "has produced improvement in tonic-clonic seizures, mixed absence with tonic-clonic seizures, and myoclonic epilepsy" may lead the reader, especially in view of the publicity in the public media before Food and Drug Administration approval, to believe that valproic acid may well be the long-sought "ideal anticonvulsant."

Since our experience with valproic acid does not parallel the findings described by Lewis and conflicts with the advance enthusiasm relative to efficacy, we would like briefly to present our results in 48 patients treated with this drug. To avoid the inherent complexities and nosologic confusion associated with the International . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?